ETOPOSIDE,
IDECABTAGENE VICLEUCEL,
BORTEZOMIB
(+6 more)
Raw JSON (click to expand)
{
"_id": "69d435813b3830196fa54cc8",
"safetyreportid": "25951372",
"authoritynumb": null,
"companynumb": "JP-STRIDES ARCOLAB LIMITED-2025OS000998",
"duplicate": 1,
"fulfillexpeditecriteria": 1,
"occurcountry": "JP",
"patient": {
"patientonsetage": 65.0,
"patientonsetageunit": 801,
"patientagegroup": null,
"patientweight": null,
"patientsex": 1,
"reaction": [
{
"reactionmeddraversionpt": "28.1",
"reactionmeddrapt": "Cytomegalovirus chorioretinitis",
"reactionoutcome": null
},
{
"reactionmeddraversionpt": "28.1",
"reactionmeddrapt": "Cytokine release syndrome",
"reactionoutcome": 6
},
{
"reactionmeddraversionpt": "28.1",
"reactionmeddrapt": "Off label use",
"reactionoutcome": 6
}
],
"drug": [
{
"drugcharacterization": 1,
"medicinalproduct": "ETOPOSIDE",
"drugauthorizationnumb": "019557",
"drugbatchnumb": null,
"drugstructuredosagenumb": null,
"drugstructuredosageunit": null,
"drugseparatedosagenumb": null,
"drugintervaldosageunitnumb": null,
"drugintervaldosagedefinition": null,
"drugcumulativedosagenumb": null,
"drugcumulativedosageunit": null,
"drugdosagetext": "2 COURSES",
"drugdosageform": "Unknown",
"drugadministrationroute": "065",
"drugindication": "Plasma cell myeloma refractory",
"drugstartdateformat": null,
"drugstartdate": null,
"drugenddateformat": null,
"drugenddate": null,
"drugtreatmentduration": null,
"drugtreatmentdurationunit": null,
"drugrecurreadministration": null,
"drugadditional": 3,
"actiondrug": 5,
"activesubstance": {
"activesubstancename": "ETOPOSIDE"
},
"drugrecurrence": []
},
{
"drugcharacterization": 1,
"medicinalproduct": "IDECABTAGENE VICLEUCEL",
"drugauthorizationnumb": null,
"drugbatchnumb": null,
"drugstructuredosagenumb": null,
"drugstructuredosageunit": null,
"drugseparatedosagenumb": null,
"drugintervaldosageunitnumb": null,
"drugintervaldosagedefinition": null,
"drugcumulativedosagenumb": null,
"drugcumulativedosageunit": null,
"drugdosagetext": "UNK",
"drugdosageform": "Infusion",
"drugadministrationroute": "065",
"drugindication": "Plasma cell myeloma refractory",
"drugstartdateformat": null,
"drugstartdate": null,
"drugenddateformat": null,
"drugenddate": null,
"drugtreatmentduration": null,
"drugtreatmentdurationunit": null,
"drugrecurreadministration": null,
"drugadditional": 3,
"actiondrug": 5,
"activesubstance": {
"activesubstancename": "IDECABTAGENE VICLEUCEL"
},
"drugrecurrence": []
},
{
"drugcharacterization": 1,
"medicinalproduct": "BORTEZOMIB",
"drugauthorizationnumb": null,
"drugbatchnumb": null,
"drugstructuredosagenumb": null,
"drugstructuredosageunit": null,
"drugseparatedosagenumb": null,
"drugintervaldosageunitnumb": null,
"drugintervaldosagedefinition": null,
"drugcumulativedosagenumb": null,
"drugcumulativedosageunit": null,
"drugdosagetext": "2 COURSES",
"drugdosageform": null,
"drugadministrationroute": "065",
"drugindication": "Plasma cell myeloma refractory",
"drugstartdateformat": null,
"drugstartdate": null,
"drugenddateformat": null,
"drugenddate": null,
"drugtreatmentduration": null,
"drugtreatmentdurationunit": null,
"drugrecurreadministration": null,
"drugadditional": 3,
"actiondrug": 5,
"activesubstance": {
"activesubstancename": "BORTEZOMIB"
},
"drugrecurrence": []
},
{
"drugcharacterization": 1,
"medicinalproduct": "THALIDOMIDE",
"drugauthorizationnumb": null,
"drugbatchnumb": null,
"drugstructuredosagenumb": null,
"drugstructuredosageunit": null,
"drugseparatedosagenumb": null,
"drugintervaldosageunitnumb": null,
"drugintervaldosagedefinition": null,
"drugcumulativedosagenumb": null,
"drugcumulativedosageunit": null,
"drugdosagetext": "2 COURSES",
"drugdosageform": null,
"drugadministrationroute": "065",
"drugindication": "Plasma cell myeloma refractory",
"drugstartdateformat": null,
"drugstartdate": null,
"drugenddateformat": null,
"drugenddate": null,
"drugtreatmentduration": null,
"drugtreatmentdurationunit": null,
"drugrecurreadministration": null,
"drugadditional": 3,
"actiondrug": 5,
"activesubstance": {
"activesubstancename": "THALIDOMIDE"
},
"drugrecurrence": []
},
{
"drugcharacterization": 1,
"medicinalproduct": "DEXAMETHASONE",
"drugauthorizationnumb": null,
"drugbatchnumb": null,
"drugstructuredosagenumb": null,
"drugstructuredosageunit": null,
"drugseparatedosagenumb": null,
"drugintervaldosageunitnumb": null,
"drugintervaldosagedefinition": null,
"drugcumulativedosagenumb": null,
"drugcumulativedosageunit": null,
"drugdosagetext": "2 COURSES",
"drugdosageform": null,
"drugadministrationroute": "065",
"drugindication": "Plasma cell myeloma refractory",
"drugstartdateformat": null,
"drugstartdate": null,
"drugenddateformat": null,
"drugenddate": null,
"drugtreatmentduration": null,
"drugtreatmentdurationunit": null,
"drugrecurreadministration": null,
"drugadditional": 3,
"actiondrug": 5,
"activesubstance": {
"activesubstancename": "DEXAMETHASONE"
},
"drugrecurrence": []
},
{
"drugcharacterization": 1,
"medicinalproduct": "CISPLATIN",
"drugauthorizationnumb": null,
"drugbatchnumb": null,
"drugstructuredosagenumb": null,
"drugstructuredosageunit": null,
"drugseparatedosagenumb": null,
"drugintervaldosageunitnumb": null,
"drugintervaldosagedefinition": null,
"drugcumulativedosagenumb": null,
"drugcumulativedosageunit": null,
"drugdosagetext": "2 COURSES",
"drugdosageform": null,
"drugadministrationroute": "065",
"drugindication": "Plasma cell myeloma refractory",
"drugstartdateformat": null,
"drugstartdate": null,
"drugenddateformat": null,
"drugenddate": null,
"drugtreatmentduration": null,
"drugtreatmentdurationunit": null,
"drugrecurreadministration": null,
"drugadditional": 3,
"actiondrug": 5,
"activesubstance": {
"activesubstancename": "CISPLATIN"
},
"drugrecurrence": []
},
{
"drugcharacterization": 1,
"medicinalproduct": "ADRIAMYCIN",
"drugauthorizationnumb": null,
"drugbatchnumb": null,
"drugstructuredosagenumb": null,
"drugstructuredosageunit": null,
"drugseparatedosagenumb": null,
"drugintervaldosageunitnumb": null,
"drugintervaldosagedefinition": null,
"drugcumulativedosagenumb": null,
"drugcumulativedosageunit": null,
"drugdosagetext": "2 COURSES",
"drugdosageform": null,
"drugadministrationroute": "065",
"drugindication": "Plasma cell myeloma refractory",
"drugstartdateformat": null,
"drugstartdate": null,
"drugenddateformat": null,
"drugenddate": null,
"drugtreatmentduration": null,
"drugtreatmentdurationunit": null,
"drugrecurreadministration": null,
"drugadditional": 3,
"actiondrug": 5,
"activesubstance": {
"activesubstancename": "DOXORUBICIN HYDROCHLORIDE"
},
"drugrecurrence": []
},
{
"drugcharacterization": 1,
"medicinalproduct": "CYCLOPHOSPHAMIDE",
"drugauthorizationnumb": null,
"drugbatchnumb": null,
"drugstructuredosagenumb": null,
"drugstructuredosageunit": null,
"drugseparatedosagenumb": null,
"drugintervaldosageunitnumb": null,
"drugintervaldosagedefinition": null,
"drugcumulativedosagenumb": null,
"drugcumulativedosageunit": null,
"drugdosagetext": "2 COURSES",
"drugdosageform": null,
"drugadministrationroute": "065",
"drugindication": "Plasma cell myeloma refractory",
"drugstartdateformat": null,
"drugstartdate": null,
"drugenddateformat": null,
"drugenddate": null,
"drugtreatmentduration": null,
"drugtreatmentdurationunit": null,
"drugrecurreadministration": null,
"drugadditional": 3,
"actiondrug": 5,
"activesubstance": {
"activesubstancename": "CYCLOPHOSPHAMIDE"
},
"drugrecurrence": []
},
{
"drugcharacterization": 2,
"medicinalproduct": "ACYCLOVIR",
"drugauthorizationnumb": null,
"drugbatchnumb": null,
"drugstructuredosagenumb": null,
"drugstructuredosageunit": null,
"drugseparatedosagenumb": null,
"drugintervaldosageunitnumb": null,
"drugintervaldosagedefinition": null,
"drugcumulativedosagenumb": null,
"drugcumulativedosageunit": null,
"drugdosagetext": "UNK",
"drugdosageform": null,
"drugadministrationroute": "065",
"drugindication": "Antiviral prophylaxis",
"drugstartdateformat": null,
"drugstartdate": null,
"drugenddateformat": null,
"drugenddate": null,
"drugtreatmentduration": null,
"drugtreatmentdurationunit": null,
"drugrecurreadministration": null,
"drugadditional": 4,
"actiondrug": 6,
"activesubstance": {
"activesubstancename": "ACYCLOVIR"
},
"drugrecurrence": []
}
],
"summary_narrativeincludeclinical": null
},
"primarysource": {
"reportercountry": "JP",
"qualification": 3,
"literaturereference": "Kikuchi T, Watanabe M, Tsukada N, Matsumoto C, Nomura-Yogo M, Kunisada K, et al.. Cytomegalovirus Retinitis During Idecabtagene Vicleucel Therapy in Patients With Relapsed/Refractory Multiple Myeloma.. Transpl-Infect-Dis. 2025;27 (4)"
},
"primarysourcecountry": "JP",
"quarter": "2025Q4",
"receiptdate": "2025-10-23T00:00:00",
"receiptdateformat": "102",
"receivedate": "2025-10-23T00:00:00",
"receivedateformat": "102",
"receiver": {
"receivertype": 6,
"receiverorganization": "FDA"
},
"reportduplicate": [
{
"duplicatesource": "Wipro",
"duplicatenumb": "IN-Wipro-4090841-426472"
}
],
"reporttype": 1,
"safetyreportversion": 1,
"sender": {
"sendertype": 6,
"senderorganization": "Onesource Specialty Pharma"
},
"serious": 1,
"seriousnesscongenitalanomali": 2,
"seriousnessdeath": 2,
"seriousnessdisabling": 2,
"seriousnesshospitalization": 2,
"seriousnesslifethreatening": 2,
"seriousnessother": 1,
"source_file": "1_ADR25Q4.xml",
"transmissiondate": "2026-01-18T00:00:00",
"transmissiondateformat": "102"
}